An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer
Executive Summary
CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.
You may also be interested in...
Bristol Highlights Growth Is Not Coming From Opdivo Alone
Recent launches and products acquired with Celgene are helping BMS grow, CEO Caforio said, while Opdivo is moving toward resuming growth thanks to first-line NSCLC and other factors.
Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism
Sales of the Bristol PD-1 inhibitor dropped 9% year-over-year but the company says approvals in first-line NSCLC are off to a good start. Q2 saw growth for Eliquis and Revlimid despite pandemic impact.
Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals
Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication.